ASLI CEYLAN | Molecular Mechanisms Signaling | Signal Transduction Award

Published on by Cell Biologist

Prof. Dr. ASLI CEYLAN | Molecular Mechanisms Signaling | Signal Transduction Award

Prof. Dr. ASLI CEYLAN , Ankara Yildirim Beyazit University , Turkey

Dr. Aslı F. Ceylan is an accomplished pharmacologist and academic with a strong foundation in medical pharmacology and translational research. Born in Ankara, Turkey, in 1977, she has dedicated over two decades to advancing our understanding of cellular signaling pathways in disease states. After earning her degrees from Ankara University, she completed a prestigious postdoctoral fellowship at the University of Wyoming, where she began her international research journey. Currently serving at Ankara Yıldırım Beyazıt University School of Medicine, she contributes to both research and education. Fluent in Turkish, English, and Spanish, Dr. Ceylan bridges global scientific collaborations. Her work spans oxidative stress, inflammation, and cellular mechanisms in cardiovascular, metabolic, and neurodegenerative diseases. She is a prolific author and recipient of several international fellowships and project grants. Dr. Ceylan stands out as a dedicated scientist whose work contributes meaningfully to the field of signal transduction and molecular pharmacology.

Publication profile:

Orcid

✅ Strengths for the Award:

  1. Extensive Research in Signal Transduction Pathways
    Dr. Ceylan’s body of work demonstrates a consistent and high-impact focus on key signal transduction pathways—including NLRP3 inflammasome activation, mitophagy, ferroptosis, oxidative stress, and autophagy—across cardiovascular, metabolic, and neurological disease models.

  2. International Research Recognition
    She has held prestigious fellowships from NIH, the American Heart Association, and INBRE, contributing to globally relevant research while collaborating with international teams, especially in the U.S. and Europe.

  3. Strong Translational Relevance
    Her research links molecular mechanisms to potential therapies, such as her exploration of aldose reductase inhibitors, natural antioxidants, and neuroprotective compounds (e.g., rosemary extracts), bridging the gap between basic science and clinical relevance.

  4. Consistent Publication Record
    Dr. Ceylan has co-authored over a dozen peer-reviewed publications in the past three years alone, with topics directly tied to signal transduction, and published in reputable journals (e.g., Biochimica et Biophysica Acta, JACC: Basic to Translational Science).

  5. Leadership and Mentorship
    As a Principal Investigator for NIH-funded thematic research projects and an academic at a medical university, she demonstrates strong leadership, mentoring capabilities, and a sustained contribution to the scientific community.

🛠️ Areas for Improvement:

  1. Greater Focus on Human Clinical Studies
    While her animal model work is comprehensive, integrating more human cell or clinical data would increase the translational applicability of her research.

  2. Expanded Thematic Clarity in Signal Transduction
    Some of her recent works, while impactful, focus broadly on pharmacological effects of natural compounds. More thematic emphasis on specific intracellular signaling cascades (e.g., MAPK, PI3K/Akt, or JAK/STAT) could strengthen her profile specifically for a signal transduction-focused award.

  3. Visibility in Global Scientific Forums
    Increased participation as a speaker, panelist, or chair in international conferences focused on signal transduction would enhance her global academic footprint.

📘 Education:

Dr. Aslı F. Ceylan completed her entire academic training in Pharmacology at the prestigious Ankara University Faculty of Pharmacy. She earned her Bachelor of Science (B.Sc.) in Pharmacy in 1998, followed by a Master of Science (M.Sc.) in Pharmacology in 2001. Her strong interest in cellular mechanisms and drug interactions led her to pursue a Ph.D. in Pharmacology, which she successfully completed in 2007. Her doctoral research was further enhanced by a research fellowship at the National Institutes of Health (NIH) during 2004-2005, providing her hands-on experience in internationally recognized labs. This rigorous academic journey solidified her expertise in pharmacological mechanisms and preclinical modeling. Her academic training was consistently supported by competitive scholarships from the Turkish Scientific and Research Council (TÜBİTAK). Dr. Ceylan’s academic path reflects a deep commitment to understanding complex cellular systems and contributes significantly to her current role as a leader in molecular pharmacology and signal transduction.

💼 Experience:

Dr. Aslı F. Ceylan is currently a faculty member at Ankara Yıldırım Beyazıt University School of Medicine, where she serves in the Department of Medical Pharmacology. She has extensive academic and research experience spanning over 20 years. Her postdoctoral research at the University of Wyoming School of Pharmacy (2008–2009) focused on cardiovascular research, where she worked on signal transduction pathways involved in heart failure and metabolic disease. She also held a Principal Investigator (PI) role in NIH-funded INBRE research projects in the U.S. from 2011 to 2020. Dr. Ceylan has consistently contributed to multi-disciplinary research projects and collaborative studies, mentoring young researchers and postgraduate students. She has a solid background in oxidative stress, inflammation, and cellular apoptosis. Her translational approach, blending basic science with therapeutic innovation, aligns perfectly with the goals of signal transduction research. Her international exposure and consistent academic productivity make her a valuable asset to any scientific initiative.

🏆 Awards and Honors:

Dr. Aslı F. Ceylan has earned numerous national and international fellowships and honors throughout her career. She was awarded the Postdoctoral Fellowship by the American Heart Association and the University of Wyoming in 2008, which significantly propelled her research on cardiovascular signaling. She also received a Ph.D. research fellowship from the NIH (2004–2005), supporting her studies in cell signaling and oxidative stress. Domestically, she was funded by TÜBİTAK (Turkish Scientific and Research Council) for both her master’s and Ph.D. degrees. Most notably, she served as Principal Investigator for NIH INBRE Thematic Research Projects from 2011 to 2020, underlining her leadership and innovation in biomedical research. These accolades reflect her ongoing commitment to excellence in pharmacological science and her impact on the field of signal transduction, particularly in cardiovascular and neurodegenerative diseases. Her strong track record of competitive funding and recognition underscores her eligibility for the Signal Transduction Award.

🔬 Research Focus:

Dr. Ceylan’s research is centered on signal transduction pathways involved in oxidative stress, inflammation, mitophagy, and ferroptosis. Her work delves into the molecular mechanisms underlying cardiovascular diseases, diabetic complications, neurodegenerative disorders, and cancer, with a particular focus on mitochondrial function and cellular defense systems. She employs both in vivo and in vitro models to study how specific pharmacological agents modulate pathways like NLRP3 inflammasome activation, aldose reductase inhibition, and autophagy. Additionally, her recent research explores the therapeutic potential of natural compounds such as carnosol, carnosic acid, and rosemary extract in modulating redox balance and apoptotic pathways. Her interdisciplinary approach links natural product pharmacology with molecular signaling, making her contributions relevant across multiple domains. The translational value of her research, aiming to bridge the gap between bench and bedside, aligns directly with the core objectives of signal transduction studies and reinforces her eligibility for this distinguished award.

📚 Publications Top Notes:

  1. 🧬 Cardiomyocyte-specific deletion of endothelin receptor A obliterates cardiac aging via mitophagy and ferroptosis (2024)

  2. 🧫 Tackling chronic wound healing using nanomaterials: Advancements and future perspectives (2023)

  3. 🧪 Dual-acting aldose reductase inhibitor impedes oxidative stress in diabetic rat tissues (2023)

  4. 👁️ Cemtirestat induces ocular defense against glycotoxic stress in diabetic rats (2023)

  5. 🍷 NLRP3 inhibition protects against ethanol-induced cardiotoxicity in FBXL2-dependent manner (2023)

  6. 💉 Oxytocin and enalapril reduce epidural fibrosis post-laminectomy in rats (2023)

  7. 🧠 Calcium dobesilate therapy in cerebral hypoxia/reperfusion injury in rats (2023)

  8. 🧬 Beclin1 deficiency attenuates alcohol-induced cardiac dysfunction via ferroptosis inhibition (2022)

  9. 💓 Parkin insufficiency exacerbates cardiac remodeling through mitochondrial Ca2+ overload (2022)

  10. ❤️‍🩹 Beclin 1 haplosufficiency compromises stem-cell cardioprotection post-MI (2022)

🧾 Conclusion:

Dr. Aslı F. Ceylan is a highly qualified, internationally active, and academically productive researcher whose expertise lies in elucidating molecular mechanisms of disease through signal transduction pathways. Her deep involvement in studies on oxidative stress, mitochondrial dynamics, inflammation, and natural product pharmacology positions her as a valuable contributor to the advancement of molecular medicine.

Given her research output, grant leadership, and commitment to translational science, she is highly suitable for the Signal Transduction Award. Her work not only contributes to the understanding of intracellular signaling but also bridges basic research with therapeutic potential, making her a standout candidate for this recognition.

Jin-Feng Hu | Molecular Mechanisms Signaling | Distinguished Scientist Award

Published on by Cell Biologist

Prof. Jin-Feng Hu | Molecular Mechanisms Signaling | Distinguished Scientist Award

Prof. Jin-Feng Hu , School of Pharmaceutical Sciences, Taizhou University, Zhejiang 318000, PR China ,China

Dr. Jin-Feng Hu is a globally recognized natural products chemist and currently serves as the Dean and Principal Investigator at the School of Pharmaceutical Sciences, Taizhou University, Zhejiang, China. With over three decades of academic and research experience, Dr. Hu has dedicated his career to discovering and developing bioactive natural products, particularly from rare and endangered plant species endemic to China. His contributions span innovative phytochemistry, drug discovery, and chemical biology. He has previously held prestigious academic positions at Fudan University and East China Normal University. Dr. Hu’s collaborations span continents, including Germany and the USA, contributing to an impressive international research profile. His work is widely published in high-impact journals and highly cited, underscoring the scientific relevance and translational potential of his discoveries.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Prolific Contributions to Natural Products Chemistry
    Dr. Hu has made significant breakthroughs in phytochemical research, particularly focusing on rare and endangered Chinese plants, contributing both to drug discovery and biodiversity conservation.

  2. Global Research Experience
    His training and postdoctoral fellowships in leading institutions across China, Germany, and the USA (including the Hans-Knoell-Institute and the Scripps Research Institute) add to his international reputation and collaborative strength.

  3. Academic Leadership & Institutional Impact
    As a former department chair at Fudan University and current Dean at Taizhou University, Dr. Hu has not only led cutting-edge research but also shaped the academic direction of major pharmaceutical programs.

  4. High-Impact Publications
    Multiple first or last-author papers published in leading journals such as Phytochemistry, Organic Chemistry Frontiers, Bioorganic Chemistry, and Molecules—with a focus on pharmacologically relevant compounds.

  5. Innovative Research Themes
    Focused on drug resistance, inflammation, and metabolic diseases, using unique molecules like bis-diterpene heterodimers and sesquiterpenes, often with novel skeletons—this shows originality and translational potential.

⚙️ Areas for Improvement:

  1. Wider Public Recognition
    While he is highly respected in academic and pharmaceutical chemistry circles, broader science communication or participation in international awards/societies could boost global visibility.

  2. Commercialization & Patents
    Encouraging the translation of discoveries into patents or clinical trials would further highlight the real-world impact of his research.

  3. International Grant Funding
    Expansion into multinational funding sources (e.g., NIH, EU Horizon) would solidify global research integration and amplify the scale of his discoveries.

🎓 Education:

Dr. Hu earned his B.S., M.S., and Ph.D. degrees in Organic Chemistry from Lanzhou University (1986–1996). He pursued advanced training and postdoctoral research in Natural Products Chemistry at the Institute of Materia Medica, Chinese Academy of Medical Sciences, followed by a prestigious BMBF Fellowship at the Hans-Knoell-Institute (HKI) in Germany. Dr. Hu then continued his postdoctoral work in the United States—first at the University of Mississippi focusing on natural products chemistry and later at the Genomics Institute of the Novartis Research Foundation/The Scripps Research Institute, in the laboratory of renowned chemist Prof. Peter G. Schultz. His academic journey across leading institutions in China, Germany, and the US provided a robust foundation in interdisciplinary sciences and global perspectives in medicinal chemistry.

🧪 Experience:

Dr. Hu currently serves as Full Professor, Principal Investigator, and Dean of the School of Pharmaceutical Sciences at Taizhou University (2021–present). Before this, he was Chair of the Department of Natural Products Chemistry at Fudan University (2011–2021), and prior to that, Deputy Director of the MOE Key Laboratory of Brain Functional Genomics at East China Normal University (2006–2011). In each position, he has led cutting-edge research in natural products, coordinated multi-institutional collaborations, mentored numerous young scientists, and managed institutional development. His lab integrates phytochemistry, structural biology, and drug discovery platforms, focusing particularly on therapeutic leads for antimicrobial resistance, cancer, and metabolic diseases. With a career that reflects both academic excellence and applied innovation, Dr. Hu has significantly contributed to China’s leadership in pharmaceutical science.

🏆 Awards and Honors:

Dr. Hu has received multiple national and international honors, including fellowships, research grants, and awards recognizing his excellence in natural products chemistry. He was a BMBF Research Fellow in Germany, a Postdoctoral Fellow at the Novartis Genomics Institute and The Scripps Research Institute in the US, and has been a recipient of several Chinese National Natural Science Foundation awards. His leadership roles at prestigious institutions like Fudan University and East China Normal University reflect the esteem he holds within the academic community. Moreover, his publications are widely cited, and his research frequently garners attention for its innovation and societal relevance, especially in the context of preserving biodiversity and discovering drugs from endangered species. These achievements make him an outstanding candidate for a Distinguished Scientist Award.

🔬 Research Focus:

Dr. Hu’s research is centered on the discovery and development of novel bioactive compounds from rare and endangered plants endemic to China. His work emphasizes the interface of phytochemistry, chemical biology, and drug discovery, employing integrative analytical techniques like NMR, LC-MS, and bioassays. A major focus is the identification of natural inhibitors of key metabolic enzymes such as ATP-citrate lyase and ACC1, with applications in metabolic disorders and cancer. His studies also target drug-resistant bacterial infections, inflammation, and neurodegenerative diseases. By studying plants that are ecologically valuable yet scientifically underexplored, Dr. Hu not only contributes to new therapeutic leads but also aids in conservation biology and chemotaxonomy. His approach of combining traditional Chinese medicinal knowledge with modern molecular science marks him as a trailblazer in natural products-based drug discovery.

📚 Publication Top Notes:

  1. 🌲 Spiroamentotaxols A−D from Amentotaxus yunnanensis and their bioactivities – Organic Chemistry Frontiers (2025)

  2. 🍃 Fortunefuroic acids from Keteleeria fortunei via integrated dereplication approach – Phytochemistry (2025)

  3. 🌿 Benzofurans from Parrotia subaequalis with antimicrobial activity – Phytochemistry (2025)

  4. 🌸 Bis-iridoid glycosides and triterpenoids from Kolkwitzia amabilis targeting ACC1 and ACL – Molecules (2024)

  5. 🍂 Platanosides from Platanus acerifolia against drug-resistant infections – Bioorganic Chemistry (2024)

  6. 🌼 Natural products from Heptacodium miconioides and their classification significance – Phytochemistry (2024)

  7. 🌲 Tsugaforrestiacids A–O from Tsuga forrestii with ATP-citrate lyase inhibition – Phytochemistry (2024)

  8. 🌲 Terpenoids from Pseudotsuga forrestii as DRAK2 inhibitors – Journal of Molecular Structure (2024)

  9. 🍁 Anti-inflammatory flavonoids from Platanus acerifolia leaves – Phytochemistry Letters (2024)

  10. 🌴 Fortunefuroic acid J from Keteleeria hainanensis with dual inhibitory effects – Chemistry & Biodiversity (2024)

🔚 Conclusion:

Dr. Jin-Feng Hu is an exceptionally qualified candidate for the Distinguished Scientist Award. His trailblazing research in natural products chemistry, strategic leadership in academic institutions, and commitment to preserving biodiversity through medicinal innovation position him as a thought leader in his field. His work not only expands the scientific frontier of phytochemical drug discovery but also addresses urgent global health concerns such as antibiotic resistance and metabolic disease. Recognizing Dr. Hu with this award would honor a career devoted to science, mentorship, and societal benefit, while also empowering his continued excellence in the years to come.

Lijuan Deng | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Published on by Cell Biologist

Mrs. Lijuan Deng | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Mrs. Lijuan Deng , Zhongshan Institute for Drug Discovery , China

Lijuan Deng is a passionate graduate student researcher at the Zhongshan Institute for Drug Discovery in China, specializing in the molecular mechanisms underlying metabolic diseases. Her scientific curiosity centers on gene regulation, signaling pathways, and metabolic dysregulation in disease progression, particularly metabolic-associated fatty liver disease (MASLD). Her translational approach blends experimental models and bioinformatics to bridge basic science and therapeutic innovation. Lijuan has already co-authored a publication in The FASEB Journal, identifying CDKN1A as a key regulator in MASLD. She is also the inventor of a patent-pending technique for nascent RNA labeling in extracellular vesicles. Through collaborations with clinical researchers and a solid foundation in molecular biology techniques, she is positioning herself as a rising talent in cell biology. Her work promises to advance understanding and treatment of metabolic diseases.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Innovative Research: Lijuan Deng has significantly contributed to the understanding of MASLD (Metabolic-Associated Steatotic Liver Disease) by identifying CDKN1A as a key regulatory gene through integrated transcriptomic analysis and experimental validation.

  2. Translational Focus: Her research bridges molecular biology and clinical application, enhancing its impact in drug discovery and disease diagnostics.

  3. Publication Record: She is the first author of a peer-reviewed article published in The FASEB Journal (SCI-indexed), showcasing her ability to conduct and communicate high-quality research.

  4. Patent Innovation: She holds a pending patent for a novel method involving nascent RNA labeling in extracellular vesicles, showing her drive toward technological advancement and biomedical innovation.

  5. Collaborative Approach: Active collaboration with the Department of Endocrinology at Shenzhen Second People’s Hospital reflects strong interdisciplinary and clinical integration.

🧩 Areas for Improvement:

  1. Expanded Publication Portfolio: Increasing the number of peer-reviewed articles will strengthen her academic visibility and impact.

  2. Professional Networking: Engagement in international cell biology societies or conferences and obtaining professional memberships can support broader recognition and growth.

  3. Editorial/Leadership Roles: Participation in editorial boards, review panels, or student leadership roles can enrich her professional development profile.

🎓 Education:

Lijuan Deng is currently pursuing her graduate studies in molecular biology at the Zhongshan Institute for Drug Discovery, where she focuses on translational biomedical research. Her academic foundation includes advanced coursework in biochemistry, molecular genetics, and cellular signaling. Through structured academic training, she has acquired proficiency in modern laboratory methods, including RNA sequencing, qPCR, western blotting, and exosome analysis. Her education emphasizes critical thinking and scientific rigor, enabling her to design experiments, analyze data, and interpret biological outcomes. She regularly participates in academic seminars, journal clubs, and collaborative workshops to refine her scientific acumen. Her thesis research is centered around identifying novel molecular targets in MASLD, a field gaining global relevance. Lijuan’s education is not only shaping her technical capabilities but also nurturing her ambition to contribute to impactful, real-world medical solutions through cell biology research.

💼 Experience:

Lijuan Deng has gained extensive laboratory experience as a graduate student researcher at the Zhongshan Institute for Drug Discovery. Her hands-on work includes both cellular and animal models, with a strong focus on metabolic disease mechanisms. She played a key role in identifying CDKN1A as a potential MASLD progression factor, combining transcriptomic data analysis with molecular validation. Additionally, she has worked on exosome-based biomarker discovery and developed a patent-pending method for nascent RNA labeling. She collaborates with the Department of Endocrinology at Shenzhen Second People’s Hospital, providing a clinical dimension to her work. Though early in her career, her contributions to translational research are already making an impact. She is skilled in molecular biology, gene expression profiling, and therapeutic target screening. Her research experience has been shaped by interdisciplinary collaboration, scientific publications, and the ambition to innovate within the field of molecular cell biology.

🧬 Research Focus:

Lijuan Deng’s research is primarily focused on the molecular underpinnings of metabolic-associated fatty liver disease (MASLD), a key manifestation of metabolic syndrome. She investigates how dysregulated genes, signaling networks, and lipid metabolism contribute to disease initiation and progression. A major highlight of her work is identifying CDKN1A as a potential risk factor in MASLD using integrated bioinformatics and experimental techniques. Additionally, she explores the utility of extracellular vesicles as carriers of diagnostic biomarkers and therapeutic molecules. Her patent-pending work involves a novel method for labeling nascent RNA within exosomes, opening possibilities for tracking dynamic RNA communication in disease contexts. Her research strategy merges molecular biology with disease modeling, aiming to bridge laboratory discoveries with potential therapeutic strategies. Through strong collaborations and a translational research outlook, Lijuan is dedicated to uncovering actionable insights that can inform drug development for complex metabolic disorders.

📚 Publications Top Notes:

  • 🧾 “Identification of CDKN1A as a potential key risk factor in MASLD progression.” – The FASEB Journal, 2025. DOI: 10.1096/fj.202402942R

🧾 Conclusion:

Lijuan Deng stands out as an emerging researcher with strong foundations in molecular cell biology and a clear orientation toward translational science. Her innovative work in MASLD, combined with an SCI publication and a pending patent, make her a highly suitable and promising candidate for the Molecular Cell Biology Award. While she is in the early stages of her career, her achievements thus far indicate substantial potential for future contributions to the field.